15-PGDH 707, 1514
25-hydroxyvitamin D 1589
2D : 4D 1631
5-ALA 462
5-aza-2′-deoxycytidine 1116
5-fluorouracil 435
5FU toxicity 1525
6th vital sign 617
α-carotene 1580
accelerated-failure time 531
active surveillance 1467
activin 1978
activin receptor 1978
acute pain 937
ADAMs 143
adenocarcinoma 143
adenocarcinoma in situ 1451
adenovirus 448
adherence to therapy 904, 1249
adhesion 129
adjuvant chemotherapy 1257, 1678
adult height 165
advanced NSCLC 442
advanced urothelial carcinoma 1031
adverse event 612
aflibercept 598, 604
Africa 1624
age at first birth 564
AhR 43
AIS 1451
Akt 847
Akt1 713
albumin 275
alcohol consumption 234, 537, 879
alternative transcript use 1409
ambulatory patients 1244
amino-acid transporter 632
AML 108
amplification 1997
anal carcinoma 1864
anastrozole 1815
angiogenesis 598, 604, 700, 977, 1207, 1227, 1481, 1498,
angiogenesis inhibitors 455
angiogenic factors 501
animal models 1944
anthracyclines 1257
anticancer drugs 1100, 1797
anti-EGFR antibody 340
antitumour activity 53
anti-vascular therapy 469
anti-VEGF antibody 308
anti-VEGF therapy 598
anxiety 1459, 1644
apolipoproteins 1883
apoptosis 63, 469, 1518
artemis overexpression 1506
Asian 1075
aspirin 1514, 1602
ATR 291
atrophic gastritis 888
autopsy 1
axitinib 1268, 1277
AZD8055 1093
BARD1 isoforms 675
basal core promoter mutant 2010
basement membrane 1153
BCAR4 947
β-carotene 1580
β-catenin 1144, 1514
Bcl-2 1714
BCL2 967
benefits and risks 1938
benign tumours 1761
bereavement 544
beta1 integrin 1969
bevacizumab 287, 360, 658, 961, 1481
BI 2536 280
bicalutamide 1714
βIII-/βV-tubulin 823
bilateral breast cancer 549
biomarker 71, 508, 823, 840, 1009, 1031, 1354, 1384, 1518, 1729, 1754, 1883, 1987
biomarker mRNA 150
bisphosphonates 7, 1665
bladder cancer 116, 123, 469, 477, 1384, 1392, 1826
body mass index 169, 1608
bone 63, 1547
bone marrow endothelial cells 1737
bone marrow stroma 1737
bone matrix 713
bone metastases 646, 1665
bortezomib 1844
brain metastases 1454, 1075
brain-only metastatic behaviour 1454
BRCA1 675, 2005
BRCA1/2 mutation 24
BRCA2 2005
breast biomarkers 382
breast cancer 7, 12, 18, 24, 63, 71, 75, 129, 230, 375, 527, 724, 732, 748, 793, 800, 874, 947, 956, 1175, 1239, 1257, 1459, 1584, 1608, 1631, 1722, 1815, 1892, 1901, 2016
breast cancer risk 176
breast cancer subtypes 1454
breast cancer surgery 937
breast masses 224
breast surgery 1459
Breslow thickness 570
C75 300
caffeine 874
calcium channels 375
calibration 1025
calprotectin 1876
CALYPSO 588
cancer cells 1337
cancer clinical trials 1017
cancer prevalence 1195
cancer progenitors 43
cancer registration 1159
cancer screening 1938
cancer therapy 1207
cancer vaccine 1302
capecitabine 585, 1268, 1678
carbonic anhydrase IX 1131
carboplatin 442, 588, 1310
carcinoembryonic antigen-related cell adhesion molecule 1745
carcinoma 739
carotenoids 1580
case–control study 1589, 1644
castration-resistant 592
CD31 1044
CD98 632
CDK 516
CEA 266, 724
CEBPD 732
CECs 1564
cell cycle 1083
cell death 469
cell fraction 1345
cell lineage 2016
cell-cycle arrest 516
cellular radiosensitivity 1506
CEPs 1564
cervical cancer 243, 556, 918, 1445, 1574, 1917, 1956
cervical neoplasia 1624
cervical screening 243
cervix 739
cetuximab 626, 1932
chemokine 1729
chemokines/receptors 1944
chemotaxis 713
chemotherapy 7, 31, 158, 531, 549, 840, 1100, 1107, 1277, 1327, 1637, 1826
Chernobyl 994
chick chorioallantoic membrane assay 1853
childhood 183
childhood cancer 544, 1159, 1652
childhood cancer survivors 234
childhood leukaemia 1159, 1163, 1652
childhood obesity 169
choriocarcinoma 1969
chromosome instability 71
chromosome translocation 739
chronic myeloid leukaemia 904
CIN 1451
circulating endothelial cells (CEC) 1286
circulating tumour cells (CTC) 448, 1286
circumferential resection margin 1925
cirrhosis 195, 2010
cisplatin 31, 360, 604, 967, 1853
CK19 724
classical CMF 1257
cleaved tRNA 1987
clinical trials 808, 910, 1017, 1672
clonality 2016
cluster analysis 234
coffee 874
cohort 195, 1181
collagen type IV 1153
colon cancer 352, 1169, 1678, 1944
colonoscopy 417, 765
colonoscopy/*methods 1051
colorectal cancer 189, 260, 287, 340, 345, 417, 626, 667, 675, 757, 765, 831, 931, 1001, 1037, 1044, 1518, 1525, 1584, 1602, 1729
colorectal cancer mortality 255
colorectal cancer prevention 1514
colorectal cancer screening 1295
colorectal neoplasm 150, 417, 1051
combination antiretroviral therapy 1624
combination treatment 1692
co-morbidity 189, 1175, 1901
conditional power 910
CONFIRM 1044
connexin-26 1963
continual reassessment method 1022
contralateral breast cancer 221
contralateral testicular germ cell tumour 1637
copper 1488
costs 1574
COX-2 inhibitor 707
C-reactive protein 275, 1031
creatine kinase 1797
CRP 1131
cryotherapy 772
CT genes 116
cumulative incidence 1637
curcumin 1083
CXCR4 43, 491
CXCR7 antagonists 1944
CYC3 1692
cyclin D1a 1684
cyclin D1b 1684
cyclins 516
cyclodextrin 1083
cyclooxgenase 207
CYP2D6 polymorphism 230
cytokine 639, 1729
cytology 1384
daytime napping 527
DCIS 1451
debulking surgery 1069
decision curve analysis 1031
decision tree analysis 1025
deep vein thrombosis 1244
defective DNA repair 1506
degradation 684
degradome 143
delayed diagnosis 1159
demographics 1810
dental health 888
depression 1644
deprivation 765
developing countries 1445
diabetes 1608
diagnosis 260, 1220, 1876
diagnostics 1987
diet 537
dietary cadmium 895
differential splicing 675
digit ratio 1631
direct sequencing 626
discrimination 1025
disease outcome 370
disseminated tumour cell 1345
disulfiram 1488
DJ-1 1595
DLBCL 491
D-loop 2016
DNA double-strand break repair 1776
DNA hypomethylation 1116
DNA microarray 1433
Doc 814
docetaxel 435, 1233, 1268, 1474
dose banding 1100
dose escalation 1022
dose standardisation 1100
dose–response relationship 1188
dosing regimen 455
doxorubicin 37
DPD 1950
drug resistance 1399
dysregulated pathways 1722
early breast cancer 1249
EDTA 1310
education 189
EGFR 1864
EGFR inhibitor 1745
elastography 224
elderly 570
emergency 1220
EMMPRIN 667
EMT 707
endocrine therapy 549, 1249
endometrial cancer 84, 169, 370, 1997
endothelial cell 1207
EORTC 1
Ephrin A2 1737
epidemiology 176, 183, 195, 874, 895, 1188, 1451, 1652, 1901
epidermal growth factor receptor (EGFR) 1745
epigenetics 75, 375, 1423
epirubicin 71, 1257
epithelial ovarian cancer 1783
epothilones 808
ERBB2 947
ERCC1 1950
erlotinib 1820
erythropoietin 1317
erythropoietin receptor 1317
ESCC 1233
estrogen receptor signalling 1722
ethics 1022
ethnic minorities 1017
ethnicity 1908
EVX1 100
exact tests 1801
exon arrays 1409
faecal immunochemical test 1295
faecal occult blood testing 255
FAK 856
fatty acid 129
fatty acid synthase 300, 977
female breast cancer 165
fetal haemoglobin 477
fetal haemopoiesis 477
FFA2/FFAR2/GPR43 1337
FFPE 684
fibroblast growth factors 1327
fine-needle aspirates 1354
fixed dose 1100
flexible sigmoidoscopy 1295
fluorescent in situ hybridisation (FISH) 71
FOBT 1938
FOLFOXIRI 1932
FOXM1 1766
futility analysis 910
G2–M cell-cycle phase 1766
gambogic acid 1702
gastric adenocarcinoma 1125
gastric cancer 31, 137, 143, 275, 1584, 1595, 1908
GBM stem-like cells 1488
gemcitabine 411, 442, 1083, 1488
gene amplification 325
gene expression 994, 1433
gene expression microarray 508
gene expression profiling 91, 1116
genetic alterations 1418
genetics 748
genomic biomarker 340
genomic profile 1418
geographical differences 1595
germ cell tumour 1833
gestational trophoblastic tumours 1810
GFP 448
GIST 1433
Gleevec 592
glioblastoma 1481
glomerular filtration rate 1310
GPRD 1602
granulocyte colony-stimulating factor 814
GRIA2 91
gut microbiota 1337
gynaecological cancers 448
hand–foot syndrome 585, 1678
HbF 477
HBV DNA levels 2010
HBV genotypes 2010
head and neck cancer 1138
health behaviour 201, 234
health inequalities 183
hematopoietic stem cells 1302
hemodynamic response imaging 658
heparins 1244
hepatocellular carcinoma 988, 1672, 2010
HER2 800, 956, 1302
HER2-positive 793
HER2-positive breast cancer 1075
hereditary non-polyposis colorectal cancer 1783
heterogeneity 1392
HGF 793
high-resolution melting analysis 1864
histology 165
histone methylation 315
HIV 1624
HIV/AIDS 556
HNSCC 707
Hodgkin's disease 531
homologous recombination deficiency 1776
hookah 1618
hormone naïve prostate cancer 1554
hormone receptor 7
hormone refractory 592
hormone status 864
hormones 1631
hospital admissions 1213
host cells 1345
hot flushes 230
HPV 1917
HPV infection 482
HPV vaccination 1445
HRMA 626
Hsp27 63
huachansu 411
human chorionic gonadotropin 1969
human glioblastoma 462
human immune system mice 1302
human papillomavirus 243, 556, 1574, 1624
humans 1051
hypercapnia 658
hyperoxia 658
hypertension in pregnancy 176
hypoxia 291, 516, 1714
IHC 1684
IL-12 1302
IL-12p40 1956
IL-6 1956
imaging 224
imatinib 592, 1433
immune suppression 1869
immunocytochemistry 1384
immunoexpression 370
immunohistochemistry 84, 325, 1745, 1864
immunoproteasome 53
immunotherapy 116, 1116
incidence 575, 1159, 1644, 1908, 2005,
Indonesia 772
infection 931, 1163
inflammation 1534
inflammation-based prognostic score 988
inhibin B 1833
inhibitor 53
INRG 1418
integrin αvβ3 713
integrins 847
interviews as topic/methods 1051
inulin-type fructans 1337
invasion 129, 713, 739, 1374, 1969
irinotecan 435
ITGA9 1374
K- ras 1864
KDR 1044
Ki-67 632
KRAS 340, 1997
KRAS 626
KRAS mutation testing 345
lactate dehydrogenase 422
laminin 1153
lapatinib 956, 1075
LAT1 632
late effects 1833
leg length 165
length of stay 931
letrozole 1815
leukaemia 879
life expectancy 778
lifestyle 201
lipoprotein lipase 739
liver cancer 195, 334
liver perfusion 658
living alone 189
LMP2 53
LNCaP 1714
loss of heterozygosity 1776
low grade 575
low-income countries 183
luminal membrane expression 137
lung adenocarcinoma 1745
lung cancer 442, 1083, 1188, 1361, 1534, 1584, 1820
lymphadenectomy 785
lymphangiogenesis 700
lymphatic metastasis 150
lymphocytes 695, 864
lymphoma 879
M30 1286
macrophage migration inhibitory factor 1498
magnetic resonance imaging 24
malignant glioma 1481
malignant PE 1876
malignant tumours 1761
mammographic density 18
mammography 24
mass screening/methods 1051
mathematical modelling 814
MCM-2 1384
mechanistic PK/PD 814
MED12 1761
medulloblastoma 1144, 1399
melanoma 422, 455, 570, 977, 1498
men 201
meningioma 1702
menopausal hormone therapy 1181
mesothelin 137
mesothelioma 161, 1107, 1978
MET 325
MET 793
meta-analysis 1163, 1608
metabolism 1207
metachronous cancer 221
metaplasia–adenoma–carcinoma sequence 1125
metastasectomy 422
metastasis 63, 75, 129, 360, 375, 707, 724, 732, 977, 1059, 1302, 1547, 1678, 1737, 1944, 1963
metastasised colorectal cancer 961
metastatic breast cancer 1454
metastatic colorectal cancer 1932, 1950
methotrexate resistance 1810
methylation 100, 732, 1423
microarray 91, 684, 1361
microRNA 123, 352, 684, 1345, 1754, 1987
microvessel density 334
middle-income countries 183
MIF 1498, 1595
migration 1317, 847
miR-126 700
miR-204 967
miRNA 1361
miRNA-21 1169
miRNAs 1354
mismatch repair 1399
mismatch repair genes 1783
mitochondria DNA 2016
mitotic inhibitor 1692
mixed lineage leukaemia 315
MLH1 1783
MLL4 315
MLL-antisense 315
MMP-9 1554
MMPs 143
molar pregnancy 1810
molecular biomarkers 1069
molecular diagnostics 345, 1138
molecular subtypes 18, 382
mortality 1901
mother 544
MSH2 1783
MSH6 1783
mTOR inhibitors 1093
multiple myeloma 1844
multiplex bead assays 287
mutation 1997
mutation screening 1761
Myc 1144
myelodysplastic/myeloproliferative neoplasms 879
myeloma 1987
NAC1 300
N-acetylglucosaminyltransferase-IV 1969
nasopharyngeal carcinoma 1580
nass 1618
National Cancer Institute 1950
national registries 176
NCAD 1374
NEAT 1257
neoadjuvant 7
neoadjuvant chemoradiotherapy 1925
neoadjuvant chemotherapy 1233, 1892, 1925
neoadjuvant therapy 956, 961
neoplasm staging 150
neuroblastoma 967, 1409, 1418
neuronal differentiation 1144
neutropenia 814
neutrophil 695
NFκB 1488, 1554
NGR-hTNF 37
nomogram 918, 1031, 1467, 1826
noncancerous tissues 1963
non-Hodgkin lymphoma 1423
non-sentinel lymph node 1239
non-small cell lung cancer 823, 1107, 1277, 1361, 1474
non-steroidal anti-inflammatory drugs 207
normal tissue radiation injury 748
North America 1917
Notch 1207, 1374
novel sequence 388
NSAID 1602
NT5E 75
NTRK2 967
nuclear factor-κB 652
nuclear receptor 831
nutrients 1580
obesity 169
oesophageal adenocarcinoma 564, 1766
oesophageal cancer 143, 1584, 1618, 1908, 1925
oesophageal neoplasm 888
oesophagectomy 1925
oesophago-gastric cancer 435
oestrogen receptor β 831
oestrogen receptor status 165
omega-6 1737
oncological trial 1
oncology 695, 1022, 1801
one-step nucleic amplification assay 1239
optimisation 814
oral hygiene 888
oral squamous cell carcinoma 700
orlistat 977
osteonecrosis of the jaw 1665
osteopontin 840, 1131
outcome 1392, 1665
ovarian cancer 37, 360, 785, 925, 1069, 1181, 1327, 1776, 1869
ovarian clear cell carcinoma 300
ovarian serous adenocarcinoma 91
overall survival 266, 588, 1454
oxaliplatin 340, 1950
OxCap 1037
OxFU 1037
p16 cellular localisation 482
p53 334, 516
paclitaxel 31, 1268, 360, 588, 823, 1692
Paget's disease 646
palliative chemotherapy 442
PAM 1409
pancreatic cancer 280, 411, 501, 632, 1354, 1692, 2005
pancreatic head cancer 1153
pancreatic neoplasms 1883
pancreaticoduodenectomy 1883
paracentesis 925
parity 564
paternal occupation 1652
paternity 1833
pathology 1467
pathways 1220
patterns of metastasis 221
Pax8 370
pazopanib 639
PCR 116, 1392
PDGFRβ 1702
pegylated liposomal doxorubicin 588
pemetrexed 604
pepsinogen 888
performance 1025
periampullary cancer 1153
peroxisome biogenesis factor-5 739
persistence 1249
persistent pain 1459
personalised therapy 1820
PGE2 1514
PGT 707, 1514
pharmacokinetics 429, 455, 604, 1277, 1525
phase I 604, 1022, 1093
phase I oncology trials 1025
phase I study 429, 612, 1474
phase II 280, 808
phase II design 1801
phase II study 1474
pHH3 84
photoreaction 1534
pIκBα 1554
PIM kinases 491
plasma cell neoplasms 879
plasma cells 864
platelet lymphocyte ratio 1525
platelets 1564
platinum 1637
platinum drugs 1327
platinum-sensitive 588
PleureX 925
PLK1 1766
Plk1 inhibitor 280
polyADP-ribosylation 1317
polymorphism 1840
population mixing 1163
population study 1169
population-based 12, 161, 570
postmenopausal 1815
postoperative pain 937
pre-clinical cancer 527
precore mutant 2010
prediction 1009, 1409, 1826
prediction model 918
predictive biomarkers 675, 1233, 1547
predictive factor 1892
prednisone 808
preeclampsia 176
pregnancy 176
preinvasive lesions 1451
prenatal hormones 1631
prenatal stress 544
prevention and control 1051
primary care 1213, 1644
primary central nervous system lymphoma 1840
primary ductal invasive breast cancer 864
PRKCZ 388
PRL-3 352
profiling 684, 1433
prognosis 84, 100, 150, 108, 116, 334, 422, 508, 639, 695, 831, 918, 1107, 1131, 1138, 1153, 1418, 1433, 1454, 1518, 1637, 1672, 1883, 1997
prognostic biomarker 370, 667
prognostic factors 161, 632, 1009, 1227
prognostic marker 1169
prognostic model 800
prognostic score 275
progression 1059, 1392
projections 1195
proliferation 508
Prolyl hydroxylases 1423
propionate 1337
prospective cohort 831, 895
prostate cancer 100, 207, 388, 575, 592, 646, 652, 713, 778, 840, 847, 895, 1467, 1547, 1564, 1584, 1714, 1737, 1963
prostatectomy 1963
prostatic neoplasms 808
proteomics 1820
PSA 100
psychological factors 937
pyridoxine 585
pyropheophorbide-a 1534
QCancer 260
qRT–PCR 1354
quality of life 904, 1295
quantitative RT–PCR 150
RAD001 resistance 847
radiation 291, 308, 652, 994
radical cystectomy 1826
radical prostatectomy 1467
radiosensitizers 469
radiotherapy 531, 549, 840, 1361
randomised trial 585, 1917
RB 516
RCC 1131
reactive oxygen species 1488
rectal cancer 266
recurrence 1138
recurrent ovarian cancer 588
reduced tumour burden 501
referral 1220
rehabilitation care 931
relative risk 888
renal cancer 856, 1131, 1227, 1286
renal cell carcinoma 1009, 1059, 1665
renal function 1037
replication 291
residual cancer 1138
resistance 1853
reverse causation 527
rhabdomyosarcoma 1374
risk 549
risk factors 1459
risk prediction 260
route 1220
RPN2 1233
rs2736100 1001
RUNX2 1714
S-1 1474
S-1 31
S100 422
S100A4 667
sample size 1801
sarcopenia 931
Scotland 575
screening 24, 417, 757, 765, 778, 1917
screening for distress 617
screening tool 1459
screen-specific anxiety 1295
second malignancies 531
second-look surgery 785
secreted SEMA5A 501
semaphorin 501
seminoma 1754
sensitivity and specificity 24
sentinel lymph node 724
serum 956, 1729
serum biomarkers 287, 1820
serum miRNAs 1987
sex hormone 564
sex steroids 831
shear wave 224
short term survival 1244
side effects 158
signalling 1317
silica 1188
silver in-situ hybridisation 325
simulation 1801
single-visit approach 772
sitting height 165
skin 1678
skin rash 1797
sleep disturbance 527
SMAD signalling 1978
small cell lung cancer 1361
smoking 234, 537, 879, 1618
snoRNA 684
social class 1652
social support 189
socio-economic deprivation 1213
socioeconomic factors 12
socio-economic inequalities 575
socioeconomic status 189, 765
soft-tissue sarcomas 639, 1374
solid tumours 1268, 1277
somatic mutation 1761
sorafenib 455, 592, 1820
spermatogenesis 1833
Src 856
Src kinase 856
stage II 1169
staging 12, 1672
standard chemotherapy 108
STAT3 352
statistical analysis 508
stomach neoplasm 325, 537
structural variant 388
sub-Saharan Africa 556
subtypes 895
sufficient life expectancy 1025
sunitinib 1286
surgery 840, 918, 931, 1175
survival 91, 161, 275, 300, 334, 537, 757, 864, 874, 918, 1672, 1722, 1840, 1883, 1059, 1075, 1220, 1327, 2005
survival analysis 531, 695
survival prediction 1031
survivin 84
survivors 1195
survivorship 1195
symptoms 904
systematic review 243
T cells 1107, 1869
T1-3 N0 1826
tamoxifen 230
tamoxifen resistance 43, 947
tandutinib 1702
target population 1445
target validation 53
targeted therapy 947, 1227, 1665, 1978
TAS-102 429
tea 874
telomerase 448, 1844
telomerase regulation 1844
telomere 1844
telomere length 1525
temozolomide 1399
TERT–CLPTM1L 1001
testicular cancer 1833
testicular germ cell tumour 1754, 1853
TFT 429
TGF-β-activated kinase-1 129
the Glasgow Prognostic Score 988
The Netherlands 12
therapeutic target 63
third primary cancer 549
thymosin beta 15 1892
thyroid 994
TIGAR 516
time trends 1159
tissue damage 1534
tissue factor 1125
tissue microarray 482
tobacco 1618
topoisomerase 2 108
toxic death 1
toxicity 158, 308
TP53 mutation 1138
TP53 mutation status 1722
TPI 429
traditional Chinese medicine 411
trastuzumab 956, 1075
TRC 724
treatment 12, 1901
treatment response 1684
triage 617
triple-negative breast cancer 75, 1892
trust 1938
tumour angiogenesis 1853
tumour burden 1518
tumour burden and metastasis 501
tumour immunology 1729
tumour inflammatory cell infiltrate 864
tumour margin 462
tumour necrosis factor alpha (TNFα). 748
tumour regression 516
tumour suppression 315
tumour suppressor 967
tumour xenograft 315
tumour-initiating cells 462
tyrosine kinase inhibitors 1227
ultrasound 224, 469
United Kingdom 1195, 1467
uranium miners 1188
urinary bladder neoplasms 1589
urine 123
urothelial carcinoma 1384
US Veterans Affairs 195
utility 778
validation 260
vascular endothelial growth factor signalling 1722
vascular targeting agent 37
vatalanib 1044
VE-821 291
VEGF 961, 1207, 1481, 1702, 1869
VEGF trap 598
VEGF-A 700, 977
VEGFR2 1044
VEGFR-2 1869
venous thromboembolism 612
vinorelbine 442, 823
visual inspection with acetic acid (VIA) 772
vitamin D 158
vitamin D binding protein 1589
whole sentinel lymph node 1239
WNT pathway 1144
wound healing 961
young age 382
zoledronic acid 7
Change history
24 January 2013
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Keyword Index for Volume 107. Br J Cancer 107, 2035–2038 (2012). https://doi.org/10.1038/bjc.2012.533
Published:
Issue Date:
DOI: https://doi.org/10.1038/bjc.2012.533